Effect of butorphanol on visceral pain in patients undergoing gastrointestinal endoscopy: a randomized controlled trial

• Published in: BMC anesthesiology Vol. 23; no. 1; p. 93
• Main Authors: Wang, Jing, Wang, Xinyan, Liu, Haiyang, Han, Ruquan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 28.03.2023; BioMed Central; BMC
• Subjects: Abdomen; Analysis; Anesthesia; Blood pressure; Body mass index; Butorphanol; Butorphanol - administration & dosage; Cancer; Clinical trials; Colon; Colonoscopy; Double-Blind Method; Drug dosages; Endoscopy; Endoscopy, Gastrointestinal; Gastroscopy; Humans; Medical personnel; Narcotics; Nausea; Oxygen saturation; Pain; Pain, Postoperative - chemically induced; Pain, Postoperative - drug therapy; Pain, Postoperative - prevention & control; Patients; Placebos; Propofol; Propofol - administration & dosage; Surgery; Visceral pain; Visceral Pain - chemically induced; Vomiting; Beijing China; China; Visceral pain; Gastroscopy; Propofol; Colonoscopy; Butorphanol
• ISSN: 1471-2253; 1471-2253
• DOI: 10.1186/s12871-023-02053-9

Butorphanol slightly influences the respiratory and circulatory systems, has a better effect on relieving the discomfort caused by mechanical traction, and has a low incidence of postoperative nausea and vomiting (PONV). Combined butorphanol and propofol may suppress postoperative visceral pain, which is avoidable in gastrointestinal endoscopy. Thus, we hypothesized that butorphanol could decrease the incidence of postoperative visceral pain in patients undergoing gastroscopy and colonoscopy. This was a randomized, placebo-controlled, and double-blinded trial. Patients undergoing gastrointestinal endoscopy were randomized to intravenously receive either butorphanol (Group I) or normal saline (Group II). The primary outcome was visceral pain after the procedure 10 min after recovery. The secondary outcomes included the rate of safety outcomes and adverse events. Postoperative visceral pain was defined as a visual analog scale (VAS) score ≥ 1. A total of 206 patients were enrolled in the trial. Ultimately, 203 patients were randomly assigned to Group I (n = 102) or Group II (n = 101). In total, 194 patients were included in the analysis: 95 in Group I and 99 in Group II. The incidence of visceral pain at 10 min after recovery was found to be statistically lower with butorphanol than with the placebo (31.5% vs. 68.5%, respectively; RR: 2.738, 95% CI [1.409-5.319], P = 0.002), and the notable difference was in pain level or distribution of visceral pain (P = 0.006). The trial indicated that adding butorphanol to propofol results in a lower incidence of visceral pain after surgery without noticeable fluctuations in circulatory and respiratory functions for gastrointestinal endoscopy patients. Clinicaltrials.gov NCT04477733 (PI: Ruquan Han; date of registration: 20/07/2020).